A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

Stephen G. Chun, Randall Hughes, Baran D. Sumer, Larry L. Myers, John M. Truelson, Saad A. Khan, Tsung Wei Ma, Yang Xie, John S. Yordy, Susan Cooley, Jean Wu, Hak Choy, Lucien A. Nedzi

Research output: Contribution to journalArticle

4 Scopus citations


Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalCancer Investigation
Publication statusAccepted/In press - Nov 28 2016



  • Abraxane
  • cisplatin
  • erbitux
  • head and neck cancer
  • radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this